CEACAM5 and ovarian cancer: Intraperitoneal administration of MV-CEA is used in patients with recurrent ovarian cancer and leads to a dose-dependent stabilization of the disease in all patients of the higher dose levels (107 to 109 TCID50) compared to only 5 of 12 patients treated in the lower dose range (103 to 106 TCID50).